DE602004018363D1 - Kombinationen für die hcv-behandlung - Google Patents

Kombinationen für die hcv-behandlung

Info

Publication number
DE602004018363D1
DE602004018363D1 DE602004018363T DE602004018363T DE602004018363D1 DE 602004018363 D1 DE602004018363 D1 DE 602004018363D1 DE 602004018363 T DE602004018363 T DE 602004018363T DE 602004018363 T DE602004018363 T DE 602004018363T DE 602004018363 D1 DE602004018363 D1 DE 602004018363D1
Authority
DE
Germany
Prior art keywords
hepatitis
relates
combinations
virus
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004018363T
Other languages
English (en)
Inventor
Roger D Tung
Gurudatt Chandorkar
Robert B Perni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of DE602004018363D1 publication Critical patent/DE602004018363D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE602004018363T 2003-10-27 2004-10-27 Kombinationen für die hcv-behandlung Active DE602004018363D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51485303P 2003-10-27 2003-10-27
PCT/US2004/035549 WO2005042020A2 (en) 2003-10-27 2004-10-27 Combinations for hcv treatment

Publications (1)

Publication Number Publication Date
DE602004018363D1 true DE602004018363D1 (de) 2009-01-22

Family

ID=34549356

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004018363T Active DE602004018363D1 (de) 2003-10-27 2004-10-27 Kombinationen für die hcv-behandlung

Country Status (22)

Country Link
US (3) US20060003942A1 (de)
EP (1) EP1677827B1 (de)
JP (1) JP2007509950A (de)
KR (1) KR20060120162A (de)
CN (1) CN1893978A (de)
AT (1) ATE416789T1 (de)
AU (1) AU2004285503A1 (de)
BR (1) BRPI0415935A (de)
CA (1) CA2543696A1 (de)
CY (1) CY1110176T1 (de)
DE (1) DE602004018363D1 (de)
DK (1) DK1677827T3 (de)
ES (1) ES2319775T3 (de)
IL (1) IL175211A0 (de)
MX (1) MXPA06004723A (de)
NO (1) NO20062428L (de)
PL (1) PL1677827T3 (de)
PT (1) PT1677827E (de)
RU (1) RU2006118359A (de)
SI (1) SI1677827T1 (de)
WO (1) WO2005042020A2 (de)
ZA (1) ZA200603863B (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2268391A1 (en) 1996-10-18 1998-04-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
KR101370580B1 (ko) * 2004-06-08 2014-03-06 버텍스 파마슈티칼스 인코포레이티드 약학 조성물
US20070004635A1 (en) * 2005-06-02 2007-01-04 Schering Corporation Method of treating interferon non-responders using HCV protease inhibitor
MX2008001528A (es) * 2005-08-02 2008-04-04 Vertex Pharma Inhibidores de serina proteasas.
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
EP1991229A2 (de) 2006-02-27 2008-11-19 Vertex Pharmaceuticals Incorporated Kokristalle und pharmazeutische zusammensetzungen damit
JP5646814B2 (ja) * 2006-03-06 2014-12-24 アッヴィ・インコーポレイテッド Ｈｃｖを治療するためのリトナビルの組成物及び使用方法
BRPI0709567A2 (pt) 2006-03-16 2011-07-12 Vertex Pharma inibidores deuterados de protease de hepatite c
US20070218138A1 (en) * 2006-03-20 2007-09-20 Bittorf Kevin J Pharmaceutical Compositions
WO2007111866A2 (en) * 2006-03-23 2007-10-04 Schering Corporation Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
EP2007789B1 (de) 2006-04-11 2015-05-20 Novartis AG Spirozyklische HCV/HIV-Hemmer und ihre Verwendung
WO2007149382A2 (en) * 2006-06-19 2007-12-27 The Cleveland Clinic Foundation Therapeutic compositions and methods useful in treating hepatitis
KR20140004808A (ko) * 2006-07-07 2014-01-13 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학 특성의 모듈레이터
WO2008067164A2 (en) * 2006-11-15 2008-06-05 Abbott Laboratories Solid pharmaceutical dosage formulations
AU2008219704A1 (en) * 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
EP2463285A1 (de) * 2007-02-27 2012-06-13 Vertex Pharmaceuticals Inc. Kokristalle und pharmazeutische Zusammensetzungen damit
CN101796040A (zh) * 2007-07-06 2010-08-04 吉里德科学公司 治疗剂的药代动力学特性调节剂
MX2010002407A (es) * 2007-08-30 2010-03-26 Vertex Pharma Cocristales y composiciones farmaceuticas que los comprenden.
US20090082366A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched telaprevir
JP5095824B2 (ja) 2007-10-10 2012-12-12 ノバルティス アーゲー スピロピロリジン類およびｈｃｖおよびｈｉｖ感染に対するその使用
EP2444070A1 (de) * 2008-02-28 2012-04-25 Abbott Laboratories Tabletten
MX2011006333A (es) 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
JP2012513409A (ja) * 2008-12-23 2012-06-14 アボット・ラボラトリーズ 抗ウイルス化合物
EP2393359A4 (de) * 2009-02-09 2012-10-03 Enanta Pharm Inc Verbundene dibenzimidazolderivate
US8314135B2 (en) * 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
US8242156B2 (en) * 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
WO2010099432A2 (en) * 2009-02-26 2010-09-02 The Johns Hopkins University Recognition of cyp2e1 epitopes
US8101643B2 (en) * 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
EP2419404B1 (de) * 2009-04-15 2015-11-04 AbbVie Inc. Anti virale verbindungen
WO2010122087A1 (en) * 2009-04-25 2010-10-28 F. Hoffmann-La Roche Ag Methods for improving pharmacokinetics
CN103819459B (zh) * 2009-06-11 2017-05-17 艾伯维巴哈马有限公司 抗病毒化合物
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2010148006A1 (en) * 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8609648B2 (en) 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) * 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8927709B2 (en) * 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US9156818B2 (en) * 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) * 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) * 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8653070B2 (en) * 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
BR112012018529A2 (pt) 2010-01-25 2016-08-09 Enanta Pharm Inc inibidores do vírus de hepatite c, sua composição farmacêutica e seu uso, e método para inibição da replicação de um vírus contendo rna
US8623814B2 (en) * 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
US8178531B2 (en) * 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
MX2012010252A (es) * 2010-03-04 2013-02-01 Enanta Pharm Inc Agentes farmaceuticos en combinacion como inhibidores de la replicacion del virus de hepatitis c (hcv).
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
EP2555622A4 (de) 2010-04-09 2013-09-18 Enanta Pharm Inc Hemmer des hepatitis-c-virus
US8778938B2 (en) 2010-06-04 2014-07-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
WO2012021704A1 (en) * 2010-08-12 2012-02-16 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US9011833B2 (en) 2010-10-08 2015-04-21 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
EP2709455A4 (de) 2011-05-18 2014-11-05 Enanta Pharm Inc Verfahren zur herstellung von 5-azaspiro-[2.4-]heptan-6-carbonsäure und derivaten davon
RU2013155713A (ru) 2011-07-06 2015-08-20 Профибрикс Бв Составы для лечения ран
ME03009B (de) 2011-09-16 2018-10-20 Gilead Pharmasset Llc Verfahren zur behandlung von hcv
JP5808496B2 (ja) * 2011-10-10 2015-11-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ウイルス化合物
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
CN104383541A (zh) 2011-10-21 2015-03-04 艾伯维公司 用于治疗hcv的包含至少两种直接抗病毒剂和利巴韦林但无干扰素的方法
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
PL2849798T3 (pl) * 2012-05-18 2021-10-18 Replicor Inc. Kompozycje oraz sposoby obejmujące chelatowy kompleks oligonukleotydu-polipeptydu
WO2014004674A2 (en) * 2012-06-27 2014-01-03 Abbvie Inc. Methods for treating hcv
JP2015508418A (ja) 2013-01-31 2015-03-19 ギリアド ファーマセット エルエルシー ２種の抗ウイルス化合物のコンビナトリアル製剤
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
EP3089757A1 (de) 2014-01-03 2016-11-09 AbbVie Inc. Feste antivirale darreichungsformen
US10688083B2 (en) * 2015-06-30 2020-06-23 Eiger Group International, Inc. Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
JP2022540699A (ja) * 2019-07-18 2022-09-16 ウエヌイグレックオ・ファーマ インターフェロンの有害作用を減少させる方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
CN100509797C (zh) * 2001-06-11 2009-07-08 病毒化学医药公司 用作黄病毒感染抗病毒剂的噻吩衍生物
TW200510391A (en) * 2003-04-11 2005-03-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
KR20120013450A (ko) * 2003-07-18 2012-02-14 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 ｈｃｖ ｎｓ3-ｎｓ4ａ 프로테아제의 억제제
MY148123A (en) * 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
RU2006115558A (ru) * 2003-10-10 2007-11-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы сериновых протеаз, особенно hcv ns3-ns4a протеазы
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c

Also Published As

Publication number Publication date
BRPI0415935A (pt) 2007-01-02
WO2005042020A2 (en) 2005-05-12
WO2005042020A3 (en) 2005-06-23
RU2006118359A (ru) 2007-12-10
KR20060120162A (ko) 2006-11-24
SI1677827T1 (sl) 2009-06-30
PL1677827T3 (pl) 2009-06-30
EP1677827B1 (de) 2008-12-10
ES2319775T3 (es) 2009-05-12
EP1677827A2 (de) 2006-07-12
ATE416789T1 (de) 2008-12-15
CN1893978A (zh) 2007-01-10
AU2004285503A1 (en) 2005-05-12
PT1677827E (pt) 2009-03-13
US20120114604A1 (en) 2012-05-10
MXPA06004723A (es) 2006-07-05
CA2543696A1 (en) 2005-05-12
DK1677827T3 (da) 2009-03-30
IL175211A0 (en) 2006-09-05
CY1110176T1 (el) 2015-01-14
ZA200603863B (en) 2007-11-28
US20060003942A1 (en) 2006-01-05
NO20062428L (no) 2006-05-29
US20100015090A1 (en) 2010-01-21
JP2007509950A (ja) 2007-04-19

Similar Documents

Publication Publication Date Title
ATE416789T1 (de) Kombinationen für die hcv-behandlung
MY148123A (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
SG159385A1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
MX2009009176A (es) Inhibidores de serina-proteasas.
TW200518746A (en) Novel inhibitors of hepatitis C virus NS3/NS4A serine protease
ES2240446T3 (es) Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
SG155967A1 (en) Hcv ns3-ns4a protease inhibition
BRPI0410456B8 (pt) compostos inibidores de hepatite c, composição farmacêutica, uso dos mesmos, bem como artigo de fabricação
SG164376A1 (en) Hcv ns3 protease inhibitors
HK1101402A1 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
PL1987038T3 (pl) Inhibitory HCV NS5B
UY28423A1 (es) Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.-
TW200633995A (en) Andrographolide derivatives to treat viral infections
TW200700057A (en) Alpha ketoamide compounds as cysteine protease inhibitors
UA90909C2 (en) Hcv ns3 protease inhibitors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition